Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
In Vivo
  • Other Publications
    • In Vivo
    • Anticancer Research
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
In Vivo

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Advertisers
    • Editorial Board
  • Other Publications
    • Anticancer Research
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
  • About Us
    • General Policy
    • Contact
  • Visit iiar on Facebook
  • Follow us on Linkedin
Research ArticleClinical Studies

The Length of Peritoneal Surgical Manipulation Correlates with Serum CA 125 Levels

ENRICOMARIA PASQUAL, STEFANO BACCHETTI, GIOVANNI MORABITO, SERENA BERTOZZI, PIER PAOLO CAGOL and DINO DE ANNA
In Vivo January 2011, 25 (1) 105-109;
ENRICOMARIA PASQUAL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: enricomaria.pasqual@uniud.it
STEFANO BACCHETTI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
GIOVANNI MORABITO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SERENA BERTOZZI
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
PIER PAOLO CAGOL
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DINO DE ANNA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Abstract

Background: Peritoneal recovery after uncomplicated serum manipulation usually lasts 7 days and high values of serical CA 125 are measured following abdominal surgery. The aim of this study was to assess a possible correlation between peritoneal manipulation and serical CA 125 levels following abdominal surgery for benign diseases. Patients and Methods: Twenty-eight patients with abdominal benign disease were operated on. They were pooled into three groups of low, intermediate and high peritoneal manipulation, according to the extent of laparotomy and length of surgical peritoneal manipulation. Venous blood samples (5 ml) were taken from each patient 24-48 hours before surgery, 12-24 hours after surgery and on the 4th and 7th postoperative day. CA 125 levels were quantified by microparticle enzyme immunoassay. Results: After surgery, patients having high peritoneal manipulation showed significantly higher levels of CA 125 compared to the preoperative levels. In particular, the length of peritoneal manipulation was correlated with increasing levels of the marker (p<0.0001). Conclusion: Peritoneal manipulation was significantly correlated to serum CA 125 levels; therefore its role as marker of peritoneal surgical injury should be considered.

  • Peritoneal manipulation
  • abdominal surgery
  • CA 125

Cancer antigen 125 (CA 125), a high molecular-weight glycoprotein of 200,000 Da, is the antigenic determinant recognised by the murine monoclonal antibody OC-125 as described by Bast et al. (1) CA 125 neoplastic marker has been demonstrated to be useful in detecting and predicting primary neoplasms or recurrences of the female genital tract, and in particular this antigen is expressed in nearly 80% of patients with epithelial ovarian cancer (2-7). However, elevated CA 125 serum levels are also observed in other clinical conditions such as pleural and pericardial effusions, dialysis, cirrhosis of the liver with ascitic fluid, peritoneal tuberculosis, and in patients who undergo abdominal surgery for benign disease (8-15).

Peritoneal cells have been demonstrated to be a valid source of CA 125 (16-17) and are very highly produced in areas of inflammation (18). In the context that peritoneal repair after uncomplicated surgery has been demonstrated to be complete approximately on the 7th postoperative day (19), this study investigated whether the length of peritoneal manipulation is related to postoperative CA 125 blood levels in patients who have undergone abdominal surgery during the immediate postoperative period.

Patients and Methods

Eligibility criteria. Patients who had undergone surgery for abdominal diseases were enrolled in this prospective observational study. Other inclusion criteria were: no evidence of neoplastic disease, pleural effusion or ascitic fluid, normal preoperative liver and renal function. All patients gave informed consent for their participation in the study, which was approved by the local Ethics Committee.

Patients and study design. Twenty-eight consecutive patients underwent surgery for benign abdominal disease. Patient characteristics are reported in Table I. Patients were analysed and stratified according to the extent of laparotomy (in centimetres) and length of surgical peritoneal manipulation (in minutes) as follows: patients submitted to <8 cm laparotomy extension and <30 minutes of peritoneal manipulation (group 1, low manipulation), patients submitted to <8 cm laparotomy extension and 30-90 minutes of peritoneal manipulation (group 2, intermediate mani-pulation) and patients with >8 cm laparotomy extension and >90 minutes of peritoneal manipulation (group 3, high manipulation). Manipulation of the peritoneum was calculated starting from the time of incision of peritoneal surface until finishing at the closure of abdominal fascia, which completes the procedure. Patients were operated on under general or spinal anaesthesia. Surgical procedures performed are reported in Table I. One or two abdominal drainages were placed in 10/12 patients of the second group, in 5/5 patients of the third group and removed at 24 to 96 and 72 to 96 hours postoperatively, respectively. All surgical specimens were submitted for histological examination.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table I.

Patients and surgical procedures.

View this table:
  • View inline
  • View popup
  • Download powerpoint
Table II.

CA 125 serum levels at different times (mean±SD).

Biochemical assessment. Venous blood samples (5 ml) were taken from each patient 24-48 hours before surgery, 12-24 hours after surgery and on the 4th and 7th postoperative day. CA 125 concentrations in the sera were determined by microparticle enzyme immunoassay (MEIA), using OC-125 monoclonal antibody, AxSYM CA 125 assay (ABBOTT Laboratories, Diagnostic Division, Abbott Park, IL, USA). The normal value of CA 125 was considered to be less or equal than 35 UI/ml in this study.

Statistical analysis. Data are given as the mean±standard deviation (SD). Preoperative and postoperative CA 125 levels within each group and among the different groups of patients were compared by using one or two-tailed Student's t-test. Linear regression analysis was used to correlate postoperative CA 125 levels with length of peritoneal manipulation.

Results

Surgery. No patient showed evidence of cancer during surgery or on histological analysis. Mean values of operating time, extension of laparotomy and length of peritoneal manipulation were measured. Patients were pooled as follows: 11 patients submitted to <8 cm laparotomy extension and <30 minutes of peritoneal manipulation (group 1, low manipulation), 12 patients submitted to <8 cm laparotomy extension and 30-90 minutes of peritoneal manipulation (group 2, intermediate manipulation) and 5 patients with >8 cm laparotomy extension and >90 minutes of peritoneal manipulation (group 3, high manipulation).

Figure 1.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 1.

Correlation between CA 125 serum levels and duration of surgical peritoneal manipulation. r=0.6394, p<0.0001.

No intraoperative or postoperative deaths occurred. Five postoperative complications occurred in 5 patients: 1 wound seroma and 2 wound Hematomas (first group) and 2 pneumonia (second group). All complications were treated conservatively and no further peritoneal manipulations were performed.

CA 125 levels. The mean±SD levels of serical CA 125 of the three groups are reported in Table II. In the first group of patients, at different times, no significant modification of CA 125 levels occurred. In the second group (intermediate manipulation), decreasing CA 125 levels were observed immediately after the operation (p<0.001), followed by increasing values on the fourth and seventh postoperative day (p<0.05 and p<0.001 respectively). In the third group (high manipulation), progressive increasing CA 125 levels were observed starting from the preoperative to the seventh postoperative day (p<0.008). In 11/12 patients (second group) and in 5/5 (third group), the highest CA 125 level was measured on the 7th postoperative day.

There was a statistically significant correlation between the CA 125 values on the 7th postoperative day and the corresponding length of peritoneal manipulation, a (r=0.6394, p<0.0001; Figure 1).

Discussion

CA 125 is a useful but not specific tumour marker that is used worldwide for the clinical evaluation of patients with epithelial gynaecological disease (19-21) and for predicting peritoneal dissemination in patients with gastric cancer (23) or advanced non-Hodgkin's lymphoma (24-25). The low specificity of CA 125 arises from the fact that it is produced in presence of ascitic fluid, by benign ovarian cysts, by cancer (26) and peritoneal cells (17-18).

Peritoneal repair after surgery has been extensively studied and it has been demonstrated that cases of uncomplicated surgery the peritoneal repair process, is usually completed 7 days after surgery (19). Peritoneal repair correlates with postoperative CA 125 increasing levels, (24) therefore suggesting its role as a marker of mesothelial membrane irritative processes (13). Peritoneal manipulation strongly correlates with CA 125 secretion; its serical levels resulted significantly higher in 19 patients submitted to abdominal surgery compared with 21 patients operated for extraabdominal disease, even if only one blood sample was considered, 48 hours after surgery, and also some patients with cancer were enrolled (17).

In order to describe the serical CA 125 secretion profile occurring following peritoneal manipulation in uncomplicated surgery, its levels in patients were monitored during 7 postoperative days. Three peritoneal manipulation times were considered: short (group 1, less than 30 minutes), intermediate (group 2, between 30 and 90 minutes) and prolonged (group 3, more than 90 minutes), according to the mean length of the peritoneal manipulation usually required during the surgical procedures performed.

Figure 2.
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure 2.

Evaluation of serical CA 125 in the three groups of patients on the seventh postoperative day. GR 1=GROUP 1; GR 2=GROUP 2; GR 3=GROUP 3; GR1 vs. GR2: p<0.001, GR1 vs. GR3: p<0.00001, GR2 vs. GR3: p<0.006.

The results of the current study demonstrate that preoperative CA 125 levels were not statistically different among the 3 groups of patients. Furthermore, according to another report (12), on the 7th postoperative day, the maximal CA 125 levels were significantly different among the three groups (see Figure 2) and the length of peritoneal manipulation correlated with the increasing marker levels (see Figure 1).

Zeimet et al. stated that human mesothelial cells are one of the most potent sources of CA 125 in the serum and its release is five times higher than from the ovarian cancer cells (18). Considering that CA 125 has half-life of 5 days, and that the highest levels were measured after 7 days, it can be supposed that it was continuously secreted during the whole 7-day postoperative period that was investigated.

Peritoneal cell secretion of CA 125 is activated in presence of cytokines released from the system of lymphocytes, macrophages, fibroblastic and endothelial cells when peritoneal trauma or flogistic processes occur (27-28). Furthermore, CA 125 production has been found to be significantly enhanced when peritoneal cells were cultured in the presence of proinflammatory cytokines such us recombinant interleukin 1 (rIL-1), tumour necrosis factor-alpha (TNF-alpha), interferon gamma (IFN-gamma) and lipopoly-saccharide from Escherichia coli (16,18). During abdominal surgery, peritoneal injury following trauma or flogistic processes has been demonstrated to be the major cause of adhesion formation and, in their turn, adhesions are frequently involved in bowel obstruction, chronic abdominal pain and infertility (29, 32). Since serum CA 125 level is correlated to peritoneal injury, its early measurement during the post-operative period might help to identify those patients who are at high risk of adhesion formation.

In conclusion, there is an early significant in vivo peritoneal secretion of CA125 in patients who undergo abdominal surgical procedures for benign disease. The length of peritoneal reaction following surgical peritoneal injury may be revealed by the CA 125 serum levels and this marker may be useful for the prediction of the risk of developing continuous inflammatory peritoneal reaction which is, with angiogenesis, cell migration, proliferation and tissue remodelling, one of the major contributing factors in abdominal adhesion growth after surgical operations.

  • Received May 28, 2010.
  • Revision received November 9, 2010.
  • Accepted November 10, 2010.
  • Copyright © 2011 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

References

  1. ↵
    1. Bast RC,
    2. Feeney M,
    3. Lazarus H,
    4. Nadler LM,
    5. Colvin RB,
    6. Knapp RC
    : Reactivity of monoclonal antibody with human ovarian carcinoma. J Clin Invest 68: 1331-1337, 1981.
    OpenUrlPubMed
  2. ↵
    1. Jacobs I,
    2. Bast RC
    : The CA-125 tumor associated antigen: a review of the literature. Hum Reprod 4: 1-12, 1989.
    OpenUrlAbstract/FREE Full Text
    1. Van der Zee AG,
    2. Duk J,
    3. Aalders JG,
    4. Boontje AH,
    5. Ten Hoor KA,
    6. De Bruijn HW
    : The effect of abdominal surgery on the serum concentration of the tumour-associated antigen CA-125. Br J Obstet Gynecol 97: 934-938, 1990.
    OpenUrlPubMed
    1. Kenemans P,
    2. Yedema CA,
    3. Bon GG,
    4. Von Mensdorff-Pouilly S
    : CA 125 in gynecological pathology: a review. Eur J Obstet Gynecol 49: 115-124, 1992.
    OpenUrl
    1. Yedema CA,
    2. Kenemans P,
    3. Thomas CM
    : CA 125 serum levels in the early post-operative period do not reflect tumour reduction obtained by cytoreductive surgery. Eur J Cancer 29: 966-971, 1993.
    OpenUrl
    1. Fisken J,
    2. Leonard RC,
    3. Stewart M,
    4. Beattie GJ,
    5. Sturgeon C
    : The prognostic value of early CA 125 serum assay in epithelial ovarian carcinoma. Br J Cancer 68: 140-145, 1993.
    OpenUrlPubMed
  3. ↵
    1. Peters-Engl C,
    2. Obermair A,
    3. Heinzl H,
    4. Buxbaum P,
    5. Sevelda P,
    6. Medl M
    : CA 125 regression after two completed cycles of chemotherapy: lack of prediction for long-term survival in patients with advanced ovarian cancer. Br J Cancer 81: 662-666, 1999.
    OpenUrlCrossRefPubMed
  4. ↵
    1. Talbot RW,
    2. Jacobsen DJ,
    3. Nagorney DM,
    4. Malkasian GD,
    5. Ritts RE
    : Temporary elevation of CA 125 after abdominal surgical treatment for bening disease and cancer. Surg Gynecol Obstet 168: 407-411, 1989.
    OpenUrlPubMed
    1. Molina R,
    2. Filella X,
    3. Bruix J,
    4. Mengual P,
    5. Bosch J,
    6. Calvet X
    : Cancer antigen 125 in serum and ascitic fluid of patients with liver diseases. Clin Chem 37: 1379-1383, 1991.
    OpenUrlAbstract/FREE Full Text
    1. Ho-dac-Pannekeet MM,
    2. Hiralall JK,
    3. Struijk DG,
    4. Krediet RT
    : Markers of peritoneal mesothelial cells during treatment with peritoneal dialysis. Adv Perit Dial 13: 17-22, 1997.
    OpenUrlPubMed
    1. Jimenez C,
    2. Diaz C,
    3. Selgas R,
    4. Auxiliadora Bajo M,
    5. Del Peso G,
    6. Sanchez-Tomero JA
    : Peritoneal kinetics of cancer antigen 125 in peritoneal dialysis patients: the relationship with peritoneal outcome. Adv Perit Dial 15: 36-39, 1999.
    OpenUrlPubMed
  5. ↵
    1. Harkki-Siren P,
    2. Sjoberg J,
    3. Toivonen J,
    4. Tiitinen A
    : Clinical outcome and tissue trauma after laparoscopic and abdominal hysterectomy: a randomized controlled study. Acta Obstet Gynecol Scand 79: 866-871, 2000.
    OpenUrlCrossRefPubMed
  6. ↵
    1. Sevinc A,
    2. Buyukberber S,
    3. Sari R,
    4. Kiroglu Y,
    5. Turk HM,
    6. Ates M
    : Elevated serum CA-125 levels in hemodialysis patients with peritoneal, pleural or pericardial fluids. Gynecol Oncol 77: 254-257, 2000.
    OpenUrlCrossRefPubMed
    1. Mas MR,
    2. Comert B,
    3. Saglamkaya U,
    4. Yamanel L,
    5. Kuzhan O,
    6. Kuzhan O
    : Ca-125; a new marker for diagnosis and follow-up of patients with tuberculous peritonitis. Dig Liver Dis 32: 595-597, 2000.
    OpenUrlCrossRefPubMed
  7. ↵
    1. Kawanishi H,
    2. Moriishi M,
    3. Harada Y,
    4. Sakikubo E,
    5. Nagai T,
    6. Tsuchiya S
    : Necessity of correcting cancer antigen 125 appearance rates by body surface area. Adv Perit Dial 16: 22-25, 2000.
    OpenUrlPubMed
  8. ↵
    1. Zeillemaker AM,
    2. Verbrugh HA,
    3. Hoynck van Papendrecht AA,
    4. Leguit P
    : CA 125 secretion by peritoneal mesothelial cells. J Clin Pathol 47: 263-265, 1994.
    OpenUrlAbstract/FREE Full Text
  9. ↵
    1. Epiney M,
    2. Bertossa C,
    3. Weil A,
    4. Campana A,
    5. Bischof P
    : CA 125 production by the peritoneum: in-vitro and in-vivo studies. Hum Reprod 15: 1261-1265, 2000.
    OpenUrlAbstract/FREE Full Text
  10. ↵
    1. Zeimet AG,
    2. Marth C,
    3. Offner FA,
    4. Obrist P,
    5. Uhl-Steidl M,
    6. Feichtinger H
    : Human peritoneal mesothelial cells are more potent than ovarian cancer cells in producing tumor marker CA-125. Gynecol Oncol 62: 384-389, 1996.
    OpenUrlCrossRefPubMed
  11. ↵
    1. diZerega GS,
    2. Campeau JD
    : Peritoneal repair and post-surgical adhesion formation. Human Reproduction Update 6: 547-555, 2001.
    OpenUrl
    1. Meier W,
    2. Stieber P,
    3. Hasholzner U,
    4. Gropp M,
    5. Fateh Moghadam A
    : Prognostic significance of CA125 in patients with ovarian cancer and secondary debulking surgery. Anticancer Res 17(4B): 2945-2947, 1997.
    OpenUrlPubMed
  12. ↵
    1. Walach N,
    2. Gur Y
    : Leukocyte alkaline phosphatase, CA15-3, CA125 and CEA in cancer patients. Tumori 84: 360-363, 1998.
    OpenUrlPubMed
    1. Sarandakou A,
    2. Phocas I,
    3. Botsis D,
    4. Sikiotis K,
    5. Rizos D,
    6. Kalambokis D
    : Tumour-associated antigens CEA, CA125, SCC and TPS in gynaecological cancer. Eur J Gynaecol Oncol 19: 73-77, 1998.
    OpenUrlPubMed
  13. ↵
    1. Nakata B,
    2. Chung KH,
    3. Kato Y,
    4. Yamashita Y,
    5. Maeda K,
    6. Onoda N
    : Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma. Cancer 83: 2488-2492, 1998.
    OpenUrlCrossRefPubMed
  14. ↵
    1. Pabst T,
    2. Ludwing C
    : CA 125: a tumor marker in non-Hodgkin lymphomas? J Clin Oncol 13: 1827-1828, 1995.
    OpenUrlFREE Full Text
  15. ↵
    1. Ozguroglu M,
    2. Turna H,
    3. Demir G,
    4. Doventas A,
    5. Demirelli F,
    6. Mandel NM
    : Usefulness of the epithelial tumor marker CA 125 in non-Hodgkin's lymphoma. Am J Clin Oncol 22(6): 615-618, 1999.
    OpenUrlCrossRefPubMed
  16. ↵
    1. Bergmann JF,
    2. Bidart JM,
    3. George M,
    4. Beaugrand M,
    5. Levy VG,
    6. Bohuon C
    : Elevation of CA 125 in patients with benign and malignant ascites. Cancer 59: 213-217, 1987.
    OpenUrlCrossRefPubMed
  17. ↵
    1. Ohzato H,
    2. Yoshizaki K,
    3. Nishimoto N
    : Interleukin-6 as a new indicator of inflammatory status: detection of serum level of interleukin-6 and C-reactive protein after surgery. Surgery 111: 201-209, 1992.
    OpenUrlPubMed
  18. ↵
    1. Ellstrom M,
    2. Bengtsson A,
    3. Tylman M,
    4. Haeger M,
    5. Olsson JH,
    6. Hahlin M
    : Evaluation tissue trauma after laparoscopic and abdominal hysterectomy: measurements of neutrophil activation and release of interleukin-6, cortisol and C-reactive protein. J Am Coll Surg 182: 423-430, 1996.
    OpenUrlPubMed
  19. ↵
    1. Mrstik M,
    2. Kotseos K,
    3. Ma C,
    4. Chegini N
    : Increased expression of interferon-inducible protein-10 during surgically induced peritoneal injury. Wound Rep Reg 11(2):120-126, 2003.
    OpenUrl
    1. Chegini N
    : Peritoneal molecular enviroment, adhesion formation and clinical implication. Front Biosci 7: 91-115, 2002.
    OpenUrl
    1. Ozel H,
    2. Avsar FM,
    3. Topaloglu S,
    4. Sahin M
    : Induction and assessment methods used in experimental adhesion studies. Wound Rep Reg 13(4): 358-364, 2005.
    OpenUrl
  20. ↵
    1. Holmdahl L,
    2. Ivarsson LM
    : The role of cytokines, coagulation and fibrinolysis in peritoneal tissue repair. Eur J Surg 165: 1012-1019, 1999.
    OpenUrlCrossRefPubMed
PreviousNext
Back to top

In this issue

In Vivo: 25 (1)
In Vivo
Vol. 25, Issue 1
January-February 2011
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on In Vivo.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The Length of Peritoneal Surgical Manipulation Correlates with Serum CA 125 Levels
(Your Name) has sent you a message from In Vivo
(Your Name) thought you would like to see the In Vivo web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
2 + 2 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
The Length of Peritoneal Surgical Manipulation Correlates with Serum CA 125 Levels
ENRICOMARIA PASQUAL, STEFANO BACCHETTI, GIOVANNI MORABITO, SERENA BERTOZZI, PIER PAOLO CAGOL, DINO DE ANNA
In Vivo Jan 2011, 25 (1) 105-109;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
The Length of Peritoneal Surgical Manipulation Correlates with Serum CA 125 Levels
ENRICOMARIA PASQUAL, STEFANO BACCHETTI, GIOVANNI MORABITO, SERENA BERTOZZI, PIER PAOLO CAGOL, DINO DE ANNA
In Vivo Jan 2011, 25 (1) 105-109;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Patients and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • Extremely elevated CA-125 in benign ovarian disease due to stretch of the peritoneum
  • Google Scholar

More in this TOC Section

  • Evaluation of TET Family Gene Expression and 5-Hydroxymethylcytosine as Potential Epigenetic Markers in Non-small Cell Lung Cancer
  • Automated Non-coplanar Volumetric Modulated Arc Therapy Planning for Maxillary Sinus Carcinoma
  • The Influence of the Rapid Increase in the Number of Adverse Event Reports for COVID-19 Vaccine on the Disproportionality Analysis Using JADER
Show more Clinical Studies

Similar Articles

In Vivo

© 2023 In Vivo

Powered by HighWire